

Artificial Intelligence in Dermatopathology

Philipp TSCHANDL


Department of Dermatology

Thursday, July 9, 2026 - 14:40 – 15:20

Summer Academy of Dermatopathology 2026

Why do we want/need a change?

Population pyramids, EU-27, 2019 and 2050
(% share of total population)



Note: all data as of 1 January. 2019: estimates and provisional. 2050: population according to the 2019 projections, baseline variant (EUROPOP2019).

Source: Eurostat (online data codes: demo_pjangroup and proj_19np)

eurostat 

eurostat 

An overview

Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade

M. Alvaro Berbis,^{a,b,*} David S. McClintock,^c Andriy Bychlov,^d Jensen Van der Laak,^e Liron Pantanowitz,^f Jochen K. Lennerz,^g Jerome Y. Cheng,^h Brett Delahunt,ⁱ Lars Egevad,^j Catarina Eloy,^k Altan B. Faris III,^l Filippo Frassetto,^m Raimundo García del Moral,ⁿ Douglas J. Hartman,^o Markus D. Hermann,^p Eva Hollemans,^q Kenneth A. Izkowski,^r Aly Karsan,^s Mark Kriegsmann,^t Mohamed E. Salama,^u John H. Sinar,^v J. Mark Tuthill,^w Bethany Williams,^x César Casado-Sánchez,^y Victor Sánchez-Turián,^z Antonio Luna,^{aa} José Aneiros-Fernández,^{ab} and Jeanne Shen^{ac,*,†}

^aDepartment of R&D, HT Médica, San Juan de Dios Hospital, Córdoba, Spain
^bFaculty of Medicine, Autonomous University of Madrid, Madrid, Spain
^cDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
^dDepartment of Pathology, Kameda Medical Center, Kamogawa, Chiba, Japan
^eDepartment of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands
^fDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA
^gDepartment of Pathology, Center for Integrated Diagnostics, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
^hWellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
ⁱDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
^jPathology Laboratory, Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
^kDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
^lPathology Unit, Azienda Sanitaria Provinciale Catania, Gravina Hospital, Caltagirone, Italy
^mDepartment of Pathology, San Cecilio Clinical University Hospital, Granada, Spain
ⁿDepartment of Anatomic Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
^oDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
^pDepartment of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands
^qDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
^rDepartment of Pathology & Laboratory Medicine, University of British Columbia, Michael Smith Genome Sciences Centre, Vancouver, Canada
^sInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
^tDepartment of Pathology, Sonic Healthcare, Austin, TX, USA
^uDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA
^vDepartment of Pathology, Henry Ford Hospital, Detroit, MI, USA
^wDepartment of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
^xDepartment of Plastic and Reconstructive Surgery, La Paz University Hospital, Madrid, Spain
^yDepartment of General Surgery and Digestive Tract, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain
^zDepartment of Integrated Diagnostics, HT Médica, Clínica Las Nieves, Jaén, Spain
^{aa}Department of Pathology and Center for Artificial Intelligence in Medicine & Imaging, Stanford University School of Medicine, Stanford, CA, USA

Summary
Background Artificial intelligence (AI) is rapidly fuelling a fundamental transformation in the practice of pathology. However, clinical integration remains challenging, with no AI algorithms to date in routine adoption within typical anatomic pathology (AP) laboratories. This survey gathered current expert perspectives and expectations regarding the role of AI in AP from those with first-hand computational pathology and AI experience.

Methods Perspectives were solicited using the Delphi method from 24 subject matter experts between December 2020 and February 2021 regarding the anticipated role of AI in pathology by the year 2030. The study consisted of three consecutive rounds: 1) an open-ended, free response questionnaire generating a list of survey items; 2) a Likert-scale survey scored by experts and analysed for consensus; and 3) a repeat survey of items not reaching consensus to obtain further expert consensus.

Findings Consensus opinions were reached on 141 of 180 survey items (78.3%). Experts agreed that AI would be routinely and impactfully used within AP laboratory and pathologist clinical workflows by 2030. High consensus was reached on 100 items across nine categories encompassing the impact of AI on (1) pathology key performance

^{*}Corresponding author. Department of R&D, HT Médica, San Juan de Dios Hospital, Córdoba, 14011, Spain.
[†]Corresponding author. Department of Pathology and Center for Artificial Intelligence in Medicine & Imaging, Stanford University School of Medicine, Stanford, CA 94305, USA.
E-mail addresses: a.berbis@hltm.org (M.A. Berbis), jeannes@stanford.edu (J. Shen).

A systematic consensus study of 24 international experts reached 78.3% agreement that AI will be routinely and impactfully integrated into anatomic pathology workflows by 2030, with strong consensus on nine categories including KPIs, workforce changes.

By 2030, due to the integration of AI in the pathology setting ...

Key performance indicator

Result

Standardization of pre-analytical processes (staining and slicing techniques) will increase

Agree

Diagnostic accuracy will increase

Strongly agree

Diagnosis and grading of tumors will be more standardized, bringing more objectivity to the diagnosis of certain entities that are currently subject to high interobserver variability

Strongly agree

Detection of rare events (small metastases, small tumor foci) will increase

Strongly agree

Analyses will be more quantitative

Strongly agree

Completeness of reports will increase

Agree

Complexity of reports will increase

Agree

Quality of reports will increase

Agree

For the Mode, (%) designates the percentage of panellists who selected that score. AI, artificial intelligence. Item # refers to the question # on the survey questionnaire. Likert scale interpretation: *Agreement level*: 1 = disagree, 5 = Agree, 6 = Strongly agree, 7 = Very strongly agree.

Table 1: Statements on which high directional consensus was reached regarding indicators (KPIs).

Berbis M et al. Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade. eBioMedicine, 2023; 88

By 2030, the probability of these AI tools being routinely used in pathology labs is ...

AI application	Item #	Mode (%)	Mean (SD)	Median (IQR)	Likelihood
Identification of micrometastases	78	7 (50.0)	6.17 (1.09)	6.5 (6.0–7.0)	Certain
Detection of lymph node metastases	79	7 (54.2)	6.33 (0.87)	7.0 (6.0–7.0)	Certain
Quantification of IHC or IF stains, such as Ki-67, ER, PgR, PD-L1	85	7 (70.8)	6.67 (0.56)	7.0 (6.0–7.0)	Certain
Quantification of number of mitoses in H&E-stained images	86	7 (50.0)	6.33 (0.76)	6.5 (6.0–7.0)	Certain
Counting lymphocytes	87	7 (50.0)	6.42 (0.65)	6.5 (6.0–7.0)	Certain
Automated ordering of IHC for specific applications/assisting with selection of immunohistochemical stains needed	61	6 (45.8)	5.46 (0.93)	6.0 (5.0–6.0)	Very likely
Automated QA/QC of IHC positive and negative controls	62	6 (54.2)	5.75 (0.90)	6.0 (5.0–6.0)	Very likely
Proposing specific IHC or other molecular methods to solve a specific diagnostic problem	68	6 (41.7)	5.17 (1.34)	5.5 (5.0–6.0)	Very likely
Prioritization of cases (such as cases with neoplasia and infectious organisms in immunosuppressed patients)	69	6 (45.8)	5.50 (1.10)	6.0 (5.0–6.0)	Very likely
Quality control of whole-slide images (scanning process), and detection of poor-quality slides (tissue folds, poor staining)	73	6 (66.7)	6.13 (0.68)	6.0 (6.0–6.5)	Very likely
Quality improvement of whole-slide images	74	6 (62.5)	6.00 (0.92)	6.0 (6.0–6.5)	Very likely
Pre-selecting regions of interest suspicious for cancer for pathologists to view	76	7 (45.8)	6.29 (0.75)	6.0 (6.0–7.0)	Very likely
Identification of hotspot areas	77	7 (45.8)	6.25 (0.85)	6.0 (6.0–7.0)	Very likely
Detection of microorganisms (AFB, <i>H. pylori</i>)	81	6 (58.3)	6.17 (0.87)	6.0 (6.0–7.0)	Very likely
Assisting with tumor grading	82	6 (62.5)	6.21 (0.59)	6.0 (6.0–7.0)	Very likely
Quantification of eosinophils in eosinophilic esophagitis	88	6 (54.2)	6.13 (0.68)	6.0 (6.0–7.0)	Very likely
Quantitation of features (e.g., fibrosis in various organs, liver steatosis, etc.)	89	6 (62.5)	6.29 (0.55)	6.0 (6.0–7.0)	Very likely
Marking of perineural invasion, lymphovascular invasion	90	6 (50.0)	5.79 (0.98)	6.0 (5.0–6.0)	Very likely
Automated measurements (e.g., of tumor areas)	94	6 (54.2)	6.21 (0.66)	6.0 (6.0–7.0)	Very likely
Ensuring all diagnostically relevant areas on the slide are viewed prior to report finalization	95	6 (50.0)	5.42 (0.83)	6.0 (5.0–6.0)	Very likely
Mandatory 2nd reads when the pathologist diagnosis doesn't match the potential AI diagnosis (within a predefined range/%; e.g., if the AI tool detects potential tumor on a biopsy but the pathologist reads the biopsy as no evidence of tumor)	97	6 (54.2)	5.79 (0.83)	6.0 (5.0–6.0)	Very likely
Standardization of pathology reports	98	6 (66.7)	5.88 (0.68)	6.0 (6.0–6.0)	Very likely
AI-assisted laboratory workflow management, including workload assignments to pathologists, residents, and technicians	59	5 (45.8)	5.33 (1.31)	5.0 (5.0–6.0)	Likely
Detection of signet ring-cell cancer	80	5 (42.7)	5.29 (1.08)	5.0 (5.0–6.0)	Likely
Pre-selection of potentially cancer-positive samples for pathologist's review, while the bulk of clearly negative samples can be automatically processed	63	5 (45.8)	5.13 (1.26)	5.0 (5.0–6.0)	Likely
Triaging of cases to the most appropriate pathologist at the earliest possible time	64	5 (41.7)	5.08 (1.41)	5.0 (5.0–6.0)	Likely
Providing a set of differential diagnoses on difficult cases	92	5 (45.8)	5.13 (0.90)	5.0 (5.0–6.0)	Likely
Proposing specific additional tests for solving a diagnostic problem (e.g., AI algorithm suggesting STAT6 immunostaining on a spindle cell neoplasm of the pleura)	93	6 (37.5)	5.17 (1.24)	5.0 (5.0–6.0)	Likely
Import of contextually-related data on a case for quick review by the pathologist during diagnostic slide review	96	5 (58.3)	5.21 (0.72)	5.0 (5.0–6.0)	Likely
Pre-populating relevant report details from the medical record/gross description	99	5 (54.2)	5.29 (0.95)	5.0 (5.0–6.0)	Likely
Selection of the appropriate synoptic report based on prior pathology findings, including the current case gross report	100	5 (50.0)	5.38 (0.88)	5.0 (5.0–6.0)	Likely
Pre-populating reports based on AI interpretation of images	101	5 (45.8)	5.13 (1.03)	5.0 (5.0–6.0)	Likely
Finding the source of contaminants	102	5 (58.3)	5.17 (0.96)	5.0 (5.0–5.5)	Likely

Advances in computational nephropathology

David L. Hölscher^{1,2,5}, Roman D. Bülow^{1,5}, Martin Strauch^{1,5} and Peter Boor^{1,2,3,4}

¹Institute for Pathology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; ²Department for Nephrology and Clinical Immunology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; ³Electron Microscopy Facility, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; and ⁴Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia

Pathology relies on pathologists' qualitative assessment and semiquantitative measures to characterize the structural and molecular alterations of tissues. Novel analytical methods and recent advances in the computational field, particularly in artificial intelligence and deep learning in pathology, termed computational pathology, have led to widespread applications and advancement in research. Integrating computational approaches into the digital pathology workflow can facilitate the automated, high-throughput analysis of histopathologic images, thereby improving precision, reproducibility, and efficiency in pathology diagnostics. We provide a comprehensive overview of the advancements and applications of computational pathology, specifically in nephropathology. We discuss widely adopted methodological approaches, highlighting their respective strengths and limitations, including quantitative nephropathology (i.e., pathomics), deep learning-based image classification and regression, and nonimage applications (e.g., automated decision support systems for standardizing the reporting of current consensus classifications). Despite the promising potential of these approaches, several challenges remain for successful implementation in routine clinical practice. We highlight technological, regulatory, and ethical challenges, such as computational infrastructure, data privacy, and considerations of environmental sustainability. Looking toward the future, we envisage potential developments that could further transform the field. We are entering a new exciting era, where computational methods are reshaping and redefining kidney pathology, perhaps also renaming our field to "kidnAI" pathology.

Kidney International (2025) 108, 1031–1044; <https://doi.org/10.1016/j.kint.2025.06.029>
KEYWORDS: deep learning; digital pathology; kidney biopsy; pathomics
Copyright © 2025, International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).


Correspondence: Peter Boor, Institute for Pathology, Pauwelsstraße 30, 52074 Aachen, Germany. E-mail: pboor@ukaachen.de
¹DLH, RDB, and MS contributed equally.

Received 4 March 2025; revised 27 May 2025; accepted 9 June 2025; published online 19 September 2025

Editor's Note



The application of artificial intelligence-based analysis to kidney pathologic lesions has made exciting progress, made possible by the advent of scanned glass slides to create whole slide images, which then can be analyzed both for quantitation of features a pathologist might see and exciting new approaches, including subvisual features that can enhance understanding of tissue injuries. In this addition to our series on artificial intelligence and machine learning, Hölscher *et al.* from the Boor laboratory provide a review of these specific applications for kidney pathology. The review systematically defines terminology, concepts, and approaches, including machine learning to deep learning, classification, segmentation, and advances in the field of pathomics, detailing progress, potential utilization, and challenges ahead. See the Big Science, Artificial Intelligence, and Machine Learning series at <https://www.kidney-international.org/content/bigscience>.



Nephropathology provides crucial insights into kidney structure and molecular alterations at the microscopic level, remaining an essential component in the diagnosis, treatment, and research of kidney diseases. In clinical nephropathology, kidney tissue is most often obtained via kidney biopsies. Its assessment requires histopathologic workup, including light microscopy for structural alterations, immunohistochemistry for molecular markers, and, in many cases, electron microscopy for the evaluation of ultrastructural changes. Most of these methods are assessed by pathologists visually and qualitatively, still often performed in an analog manner using microscopes. Semiquantitative histopathologic measures are part of almost every kidney biopsy report. Examples include the Oxford classification of IgA nephropathy (IgAN),¹ or the Banff lesion scores used in the classification of kidney allograft pathology.² Albeit providing



Alphabet

- Agents
- AP
- CLIP
- CNN
- CPATH
- Dice
- FM
- ICC-Profiles
- IoU
- Jaccard
- k-fold CV
- LLM
- MCP
- MIL
- MPP
- NER
- Object Detection
- RAG
- Reinforcement learning
- Segmentation
- Skills
- STT
- TCGA
- Tiling
- Tokens
- Transformers
- TTS
- VLM
- Weak supervision
- Workflows
- ...






BCC, superficial: 75%
BCC, nodular: 24%

Metrics:


- Accuracy (Top 1/3/...)
- AUC
- Se/Sp/PPV/NPV
- "Mean recall"




Diagnosis \ Prediction	AKIEC	BCC	BKL	DF	MEL	NV	VASC
AKIEC	0.682	0.091	0.114		0.091	0.023	
BCC	0.032	0.849	0.032		0.032	0.054	
BKL	0.005	0.032	0.781		0.068	0.114	
DF	0.022	0.044	0.022	0.689	0.022	0.2	
MEL			0.035		0.673	0.281	0.012
NV	0.004	0.008	0.007		0.019	0.963	
VASC		0.086				0.143	0.771



Metrics:

- Se/Sp/PPV/NPV
- IoU/Jaccard, Sørensen-Dice







Metrics:

- $AP@[0.5,0.75,0.95]$

IoU-Thresholds

Area under PR-curve



- mAP = average over all classes



- Str. Corneum: **Lamellar**
- Tumor: **Basaloid cells**
- Dermis: **Solar elastosis**
- ...


Metrics:



- Like Classification



Metrics:

- Precision, Recall, F1, AP
- Discounted Cumulative Gain






Metrics:
- Custom

"Microscopy: The specimen shows a punch biopsy with a basaloid tumor reaching the upper reticular dermis and the lateral margins.

Diagnosis: Basal cell carcinoma, margins affected."

What about here?



AI-assisted basal cell carcinoma diagnosis with LC-OCT: A multicentric retrospective study

Sébastien Fischman¹ | Théo Viel¹ | Jean-Luc Perrot^{2,3} | Javiera Pérez-Anker^{4,5} |
Mariano Suppa^{6,7,8} | Elisa Cinotti^{7,9} | Clément Lenoir⁶ | Carmen Orte Cano⁶ |
Julia Welzel¹⁰ | Sandra Schuh¹⁰ | Elke Christina Sattler¹¹ | Véronique del Marmol⁶ |
Pietro Rubegni⁹ | Martina Dragotto⁹ | Vittoria Cioppa⁹ | Francesca Falcinelli⁹ |
Simone Cappilli^{12,13} | Steven Challe¹ | Clara Tavernier¹ | Josep Malvehy^{4,5} |
Linda Tognetti⁹ | LC-OCT Reviewers Consortium

¹Damae Medical, Paris, France

²Department of Dermatology, University Hospital of Saint-Etienne, Saint-Etienne, France

³UMR CNRS 5516 Laboratoire Hubert Curien, Saint-Etienne, France

⁴Melanoma Unit, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain

⁵CIBER de enfermedades raras, Instituto de Salud Carlos III, Barcelona, Spain

⁶Department of Dermatology, Hôpital Erasme, HUB, Université Libre de Bruxelles, Brussels, Belgium

⁷Groupe d'Imagerie Cutanée Non Invasive (GICNI) of the Société Française de Dermatologie (SFD), Paris, France

⁸Department of Dermato-Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

⁹Dermatology Unit - Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy

¹⁰Department of Dermatology and Allergy, University Hospital, University of Augsburg, Augsburg, Germany

¹¹Department of Dermatology and Allergy, University Hospital, LMU, Munich, Germany

¹²Dermatologia, Dipartimento di Medicina e Chirurgia Traslationale, Università Cattolica del Sacro Cuore, Rome, Italy

¹³UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy

Correspondence

Sébastien Fischman, Damae Medical, 14 rue
Sthrau, Paris 75013, France.
Email: sebastien@damae-medical.com

Abstract

Background: Basal cell carcinoma (BCC) is the most common skin cancer, requiring an early diagnosis and accurate margin definition to prevent functional and cosmetic complications. Traditional methods using clinical and dermoscopic images (C&D) often rely on biopsies and histology for final validation. Non-invasive techniques like LC-OCT, enabling 'digital biopsies', are promising alternatives, but remain underutilized due to the expertise required. The development of Artificial Intelligence (AI) algorithms is a promising approach to assist dermatologists in their diagnosis and support the broader adoption of such technologies.

Objectives: We present a real-time AI assistant for BCC diagnosis with LC-OCT, which is, to date, the only real-time AI model across all dermatological imaging modalities. The study aims to quantify the model's effectiveness when used by dermatologists with different levels of expertise and compare its performance with traditional methods and unaided LC-OCT.


Josep Malvehy and Linda Tognetti: co-senior authorship.

The members of LC-OCT Reviewers Consortium are presented in Acknowledgements.

Linked Article: B.-Y. Gao and Y.-T. Lee. *J Eur Acad Dermatol Venerol* 2026;40:e508–e509. <https://doi.org/10.1111/jdv.70276>.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](#) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2025 The Author(s). *Journal of the European Academy of Dermatology and Venerology* published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venerology.

AI-assisted LC-OCT improved diagnostic accuracy by 20.3 percentage points (from 72.7% to 93.0%) compared to traditional methods, effectively bridging a 2-year experience gap for dermatologists with limited expertise.



Diagnosis


Superficial BCC

Correct answers without AI

74,42%

Correct answers with AI

97,67% (+23,25%)



Diagnosis

Nodular BCC


Correct answers without AI

51,16%

Correct answers with AI

88,37% (+37,21%)

Can we predict metastases from dermatoscopy?




Prediction of melanoma metastasis using dermatoscopy deep features: an international multicentre cohort study

Konstantinos Lallas¹, Panagiota Spyridonos, Harald Kittler, Philipp Tschandl, Konstantinos Liopyris, Giuseppe Argenziano, Renato Bakos, Ralph Braun, Horacio Cabo, Emi Dika, Josep Malvehy, Ash Marghoob, Susana Puig, Alon Scope, Wilhelm Stolz, Masaru Tanaka, Luc Thomas, Zoe Apalla, Efstratios Vakirlis, Iris Zalaudek, Aimilios Lallas


Train 600 patients (200 metastatic)
Test 112 patients (47 metastatic)

[**model 1**] accurately predicted metastasis in 21 of 23 (**91%**) **stage IIB** melanomas and in 21 of 23 (**91%**) **stage IIC** melanomas, whereas model 2 (Breslow thickness and ulceration) correctly predicted metastasis in 87% and 91% of IIB and IIC melanomas, respectively




Model 1: CNN
Model 2: Breslow+Ulcer
Model 3. CNN+Breslow+Ulcer

→ Automated image analysis of **pre-histologic** imaging can be a prognostic **staging** method



A simplified topology of digital pathology



GrandQC adaptation as an artificial intelligence tool for quantitative artifact detection in hematoxylin and eosin whole-slide images—Simulation of quality control biopsies day

Gonalo Borrecho^{a,b,c,d,e,i,*}, Pedro Nina^{c,f}, Ricardo Santos^g, In s Ferreira^h, Pedro Salgueiroⁱ, Catarina Madeira^d, Lu s Ratoⁱ, Rui Caetano Oliveira^h

^a NOVA National School of Public Health, NOVA University Lisbon, Lisbon, Portugal

^b Comprehensive Health Research Centre (CHRC), NOVA Medical School, Lisbon, Portugal

^c Pathology Department, Unidade Local de Sa de de Coimbra (CHUC), Coimbra, Portugal

^d CoLAB TRIALS Association,  vora, Portugal

^e Egas Moniz Center for Interdisciplinary Research (CIEM), Monte de Caparica, Portugal

^f Human Genetic Department, Instituto Nacional de Sa de Doutor Ricardo Jorge (INSA), Lisbon, Portugal

^g Nova Information Management School (IMS), Lisbon, Portugal

^h Centro de Anatomia Patol gica Germano de Sousa (CAPGS), Coimbra, Portugal

ⁱ VISTA Lab, Centro Algoritmi, Universidade de  vora (UE),  vora, Portugal

ARTICLE INFO

Keywords:

Digital pathology
Computational pathology
Artificial intelligence
Quality control

ABSTRACT

Introduction: Digital pathology continues to transform the daily routine of pathology, in terms of the increasingly automated laboratory and in the diagnostic paradigm through the adoption of artificial intelligence (AI) tools to support diagnosis—computational pathology. The reliability and performance of these tools depend on the whole-slide image (WSI) quality being guaranteed a priori. Pre-analytical quality control step that underpins this guarantee, and artifact detection remains largely qualitative and is frequently overlooked in routine digital pathology. This operational feasibility study evaluated whether an adaptation of GrandQC, an open-source AI tool, enables automated, quantitative artifact assessment of a complete single-day biopsy workload from a high-throughput digital pathology laboratory, analyzed retrospectively.

Material and methods: A random biopsies day of 2025 at Centro de Anatomia Patol gica Germano de Sousa (CAPGS) was selected as a sample to test the performance of GrandQC on the WSI generated ($n = 544$) in order to simulate the daily workflow. A script was created to quantify the pixels corresponding to the type of artifact automatically, creating an Excel file for registering and statistical analysis.

Results: Analysis took a median of 24 s per WSI, detecting a median of 1.46% of tissue area with some type of artifact. Dark Spots and blurring areas were the most representative detected artifacts.

Conclusion: GrandQC is a valuable tool in the quantitative quality control of biopsies tissue, allowing quick evaluation, signaling types of artifacts, and identifying cases that need to be reviewed before being handed over to the pathologist allowing the recognition of opportunities to improve laboratory histology quality and precision medicine.

Introduction

Digital pathology represents a profound transformation in pathological anatomy lab, enabling the transition from conventional microscopes to the computational analysis of digitized histological slides—whole-slide images (WSI).^{1–6} At the heart of this revolution is deep learning (DL), an advanced artificial intelligence (AI) technology that uses neural networks to analyze these digital images. DL systems have demonstrated their ability to achieve

remarkable accuracy, rivaling that of human pathologists in tasks such as prostate cancer detection, where accuracy can exceed 98%,⁷ in support in routine, laborious, and repetitive situations such as the determination of the grade of infection by *Helicobacter pylori*, mitosis scoring in breast cancer, as well as in the determination of predictive biomarkers without the use of complementary diagnostic techniques such as HER2, microsatellite instability, and EGFR mutations, despite these resources only being available for research.^{8–12} This change enables the integration of DL algorithms for




* Corresponding author at: Unidade Local de Sa de de Coimbra, E.P.E. Pathology Department, Av. Bissaya Barreto - Praceta Prof. Mota Pinto 3000-075, Coimbra, Portugal.
E-mail address: 19308@ulsc Coimbra.min-saude.pt (G. Borrecho).

<https://dx.doi.org/10.1016/j.jpi.2026.100682>


Received 25 January 2026; Received in revised form 3 June 2026; Accepted 6 June 2026


Available online 11 June 2026

2153-3539/  2026 The Author(s). Published by Elsevier Inc. on behalf of Association for Pathology Informatics. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).





A simplified topology of digital pathology





- Reducing review time
- Reducing navigation burden



Orientation Normalization of Multi-Stain Skin Tissue Cross-Sections

Ema Topolnjak^{1,2}

Evi Paulides¹

Willeke A. M. Blokk³

Mitko Veta¹

Ruben T. Lucassen^{1,3}

R.T.LUCASSEN@UMCUTRECHT.NL

¹ Dept. of Biomedical Engineering, Eindhoven University of Technology, the Netherlands

² Dept. of Electrical and Computer Engineering, Vanderbilt University, Nashville, TN, USA

³ Dept. of Pathology, University Medical Center Utrecht, the Netherlands

Editors: Accepted for publication at MIDL 2026

Abstract

Efficient examination of skin tissue specimens is key for pathologists to keep up with an increasing workload. Normalizing the orientation of tissue cross-sections before manual assessment could contribute to a more streamlined digital workflow. In this study, we compare multiple deep learning-based approaches for predicting the rotation angle required to correct the misorientation of skin tissue cross-sections. The models were developed and evaluated using a dataset of 10,649 H&E-stained and 9,731 IHC-stained cross-section images from specimens with melanocytic lesions. Our results show that framing rotation angle prediction as a classification task with the circular target space divided into separate classes performed best, reaching mean absolute errors of 2.77° and 3.56° on the test sets of H&E and IHC-stained cross-sections, respectively, approaching the level of human annotators. Automated orientation normalization, when implemented in whole slide image viewers, could make tissue examination more efficient and convenient for pathologists, while also serving as a valuable preprocessing step for the development of position-aware or multi-stain deep learning models.

Keywords: Classification, Regression, Rotation Angle, Computational Pathology, Melanoma

1. Introduction


Whole slide imaging has enabled the transition from conventional, microscope-based tissue examination to fully digital pathology diagnostics, offering benefits such as digital archiving, remote working, as well as computational image analysis to assist pathologists (Stathonikos et al., 2013, 2020). Before a tissue specimen can be examined, however, it undergoes a histological preparation process, which includes tissue fixation, paraffin embedding, microtome sectioning, and staining. During the preparation process, tissue sections are often placed on the glass slides with an arbitrary orientation. Unlike tissue sections of most organ types, cross-sections of skin tissue specimens typically have an ideal orientation (i.e., the epidermis positioned at the top to reflect the natural outside-to-inside structure) and are, therefore, frequently misoriented, impeding optimal histological examination.

© 2026 CC-BY 4.0, E. Topolnjak, E. Paulides, W.A.M. Blokk, M. Veta & R.T. Lucassen.


Model with mean absolute errors of 2.77°-3.56°

1. Automated rotation is possible
2. Relevant publications in computational medicine come from conferences (MIDL 2026)
3. The model is open source & free to use:

https://huggingface.co/RTLucassen/orientation_normalization



→ Automated analyses can provide
unprecedented **insight and** improve
workflow **efficiency**



Weakly supervised deep learning image analysis can differentiate melanoma from naevi on haematoxylin and eosin-stained histopathology slides

Nigel G. Maher^{1,2,3} | Homay Danaei Mehr⁴ | Cong Cong⁴ | Nurudeen A. Adegoke^{1,2,5} | Ismael A. Vergara^{1,2,5} | Sidong Liu⁴ | Richard A. Scolyer^{1,2,3,5} 

¹Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia

²Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

³Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia

⁴Centre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia

⁵Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia

Correspondence

Richard A. Scolyer, Melanoma Institute Australia, The University of Sydney, 40 Rocklands Road, North Sydney, NSW 2060, Australia.
Email: richard.scolyer@health.nsw.gov.au

Funding information

Royal College of Pathologists of Australasia, Grant/Award Number: PostgraduateResearchFellowship2022; University of Sydney; National Health and Medical Research Council, Grant/Award Number: 2022/GNT2018514; Melanoma Institute Australia; Tour de Cure Ltd, Grant/Award Number: GC0103-2022

Abstract

Background: The broad histomorphological spectrum of melanocytic pathologies requires large data sets to develop accurate and generalisable deep learning (DL)-based diagnostic pathology classifiers. Weakly supervised DL promotes utilisation of larger training data sets compared to fully supervised (patch annotation) approaches. **Objectives:** To evaluate weakly supervised DL image classifiers for discriminating melanomas from naevi on haematoxylin and eosin (H&E)-stained pathology slides. **Methods:** A representative H&E slide for 260 naevi and 260 melanomas from mucocutaneous sites at one tertiary institution was digitized. Clinicopathological features were recorded for each case including thickness and histological subtype. Whole-slide or whole-tissue section labels were applied. The ground truth was established by consensus diagnosis from two pathologists. Multiple-instance learning models, Trans-MIL, CLAM and DTFD-MIL were evaluated at 10×, 20× and 40× magnifications using stratified fivefold Monte Carlo cross-validation, with 80/10/10 splits for training/validation/test groups, to predict melanoma from naevus. Heatmaps were generated to understand model performance.

Results: Naevi cases were younger (median age: 51 years; melanoma median age: 71.5 years), with more balanced sex distribution (males: 48.8%, melanoma male subgroup: 64.2%). The most frequent histological subtypes of naevi and melanomas were dysplastic compound ($n=99$, 38.1%) and superficial spreading ($n=124$, 47.7%), respectively. Average AUC (± 1 SD) for Trans-MIL, CLAM and DTFD-MIL across test groups were 0.9952 ± 0.006 , 0.9925 ± 0.0052 and 0.9708 ± 0.0328 , at 20× magnification, respectively. Performance of the models varied according to the magnification used. Heatmaps from the two best performing models, Trans-MIL and CLAM, generally indicated attention on appropriate tissue regions for interpretation.

Conclusions: Weakly supervised DL on pathological slides of common mucocutaneous melanocytic tumours provides highly accurate diagnostic value for discrimination of melanomas and naevi. External validation and further assessment on less frequently occurring histologic subtypes and borderline cases using this method is required.

INTRODUCTION

Pathological diagnosis of melanomas and naevi can be challenging and subjective.¹ The development of reliable

and accurate adjunctive tools to support pathologist interpretation of melanocytic pathology is required. While adjunctive tools to date have focused on immunohistochemistry stains (e.g. PRAME) and genomic ancillary


Linked article: S. P. Clark. *J Eur Acad Dermatol Venerol* 2024;38:2209–2210. <https://doi.org/10.1111/jdv.20382>.

© 2024 European Academy of Dermatology and Venerology.

2250 | [wileyonlinelibrary.com/journal/jdv](https://www.wileyonlinelibrary.com/journal/jdv)


J Eur Acad Dermatol Venerol. 2024;38:2250–2258.

„Weakly-supervised“



“Basal cell carcinoma”

„MIL“



“Basal cell carcinoma”

Foundation models

Weakly supervised deep learning image analysis can differentiate melanoma from naevi on haematoxylin and eosin-stained histopathology slides

Nigel G. Maher^{1,2,3} | Homay Danaei Mehr⁴ | Cong Cong⁴ | Nurudeen A. Adegoke^{1,2,5} | Ismael A. Vergara^{1,2,5} | Sidong Liu⁴ | Richard A. Scolyer^{1,2,3,5} 

¹Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia

²Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

³Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia

⁴Centre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia

⁵Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia

Correspondence

Richard A. Scolyer, Melanoma Institute Australia, The University of Sydney, 40 Rocklands Road, North Sydney, NSW 2060, Australia.
Email: richard.scolyer@health.nsw.gov.au

Funding information

Royal College of Pathologists of Australasia, Grant/Award Number: PostgraduateResearchFellowship2022; University of Sydney; National Health and Medical Research Council, Grant/Award Number: 2022/GNT2018514; Melanoma Institute Australia; Tour de Cure Ltd, Grant/Award Number: GC0103-2022

Abstract

Background: The broad histomorphological spectrum of melanocytic pathologies requires large data sets to develop accurate and generalisable deep learning (DL)-based diagnostic pathology classifiers. Weakly supervised DL promotes utilisation of larger training data sets compared to fully supervised (patch annotation) approaches. **Objectives:** To evaluate weakly supervised DL image classifiers for discriminating melanomas from naevi on haematoxylin and eosin (H&E)-stained pathology slides. **Methods:** A representative H&E slide for 260 naevi and 260 melanomas from mucocutaneous sites at one tertiary institution was digitized. Clinicopathological features were recorded for each case including thickness and histological subtype. Whole-slide or whole-tissue section labels were applied. The ground truth was established by consensus diagnosis from two pathologists. Multiple-instance learning models, Trans-MIL, CLAM and DTFD-MIL were evaluated at 10×, 20× and 40× magnifications using stratified fivefold Monte Carlo cross-validation, with 80/10/10 splits for training/validation/test groups, to predict melanoma from naevus. Heatmaps were generated to understand model performance.

Results: Naevi cases were younger (median age: 51 years; melanoma median age: 71.5 years), with more balanced sex distribution (males: 48.8%, melanoma male subgroup: 64.2%). The most frequent histological subtypes of naevi and melanomas were dysplastic compound ($n=99$, 38.1%) and superficial spreading ($n=124$, 47.7%), respectively. Average AUC (± 1 SD) for Trans-MIL, CLAM and DTFD-MIL across test groups were 0.9952 ± 0.006 , 0.9925 ± 0.0052 and 0.9708 ± 0.0328 , at 20× magnification, respectively. Performance of the models varied according to the magnification used. Heatmaps from the two best performing models, Trans-MIL and CLAM, generally indicated attention on appropriate tissue regions for interpretation.

Conclusions: Weakly supervised DL on pathological slides of common mucocutaneous melanocytic tumours provides highly accurate diagnostic value for discrimination of melanomas and naevi. External validation and further assessment on less frequently occurring histologic subtypes and borderline cases using this method is required.

INTRODUCTION

Pathological diagnosis of melanomas and naevi can be challenging and subjective.¹ The development of reliable

and accurate adjunctive tools to support pathologist interpretation of melanocytic pathology is required. While adjunctive tools to date have focused on immunohistochemistry stains (e.g. PRAME) and genomic ancillary

Full dataset: 260 naevi + 260 melanomas
Average AUC: 0.99

Histological Subtype	Test Fold 1, <i>n</i> (%) (<i>N</i> =52)	Test Fold 2, <i>n</i> (%) (<i>N</i> =52)	Test Fold 3, <i>n</i> (%) (<i>N</i> =52)	Test Fold 4, <i>n</i> (%) (<i>N</i> =52)	Test Fold 5, <i>n</i> (%) (<i>N</i> =52)
Naevus subtype (<i>n</i> =26)					
Dysplastic compound	7 (13.5)	11 (21.2)	10 (19.2)	11 (21.2)	10 (19.2)
Dysplastic junctional	6 (11.5)	3 (5.8)	4 (7.7)	5 (9.6)	3 (5.8)
Dermal	7 (13.5)	10 (19.2)	7 (13.5)	7 (13.5)	6 (11.5)
Common compound	3 (5.8)	0 (0)	2 (3.8)	1 (1.9)	4 (7.7)
Blue	2 (3.8)	1 (1.9)	2 (3.8)	2 (3.8)	1 (1.9)
Combined	1 (1.9)	1 (1.9)	0 (0)	0 (0)	2 (3.8)
Acral	0 (0)	0 (0)	1 (1.9)	0 (0)	0 (0)
Melanoma subtype (<i>n</i> =26)					
Superficial spreading	10 (19.2)	11 (21.2)	12 (23.1)	11 (21.2)	10 (19.2)
Nodular	6 (11.5)	2 (3.8)	2 (3.8)	7 (13.5)	7 (13.5)
Lentigo maligna (invasive)	2 (3.8)	7 (13.5)	7 (13.5)	3 (5.8)	4 (7.7)
Pure desmoplastic	3 (5.8)	0 (0)	1 (1.9)	1 (1.9)	0 (0)
Mixed desmoplastic	0 (0)	2 (3.8)	1 (1.9)	1 (1.9)	0 (0)
Metastasis	1 (1.9)	1 (1.9)	1 (1.9)	2 (3.8)	1 (1.9)
Acral	2 (3.8)	1 (1.9)	2 (3.8)	1 (1.9)	2 (3.8)
Melanoma in-situ	1 (1.9)	1 (1.9)	0 (0)	0 (0)	2 (3.8)
Mucosal	1 (1.9)	1 (1.9)	0 (0)	0 (0)	0 (0)

Linked article: S. P. Clark. J Eur Acad Dermatol Venerol 2024;38:2209–2210. <https://doi.org/10.1111/jdv.20382>.

© 2024 European Academy of Dermatology and Venerology.



<https://doi.org/10.1038/s44385-025-00013-1>

Artificial intelligence-based triaging of cutaneous melanocytic lesions

Ruben T. Lucassen^{1,2}, Nikolas Stathonikos¹, Gerben E. Breimer¹, Mitko Veta^{2,3} & Willeke A. M. Blokx^{1,3}

Check for updates


Pathologists are facing an increasing workload due to a growing volume of cases and the need for more comprehensive diagnoses. Aiming to facilitate workload reduction and faster turnaround times, we developed an artificial intelligence (AI) model for triaging cutaneous melanocytic lesions based on whole slide images. The AI model was developed and validated using a retrospective cohort from the University Medical Center Utrecht, the Netherlands. The dataset consisted of 52,202 whole slide images from 27,167 unique specimens, acquired from 20,707 patients. Specimens with only benign common nevi, also known as moles, were assigned to the low complexity category (86.6%). In contrast, specimens with any other melanocytic lesion subtype, including non-common nevi, melanocytomas, and melanomas, were assigned to the high complexity category (13.4%). The dataset was split on patient level into a development set (80%) and test sets (20%) for independent evaluation. Predictive performance was primarily measured using the area under the receiver operating characteristic curve (AUROC) and the area under the precision–recall curve (AUPRC). A simulation experiment was performed to study the effect of implementing AI-based triaging in the clinic. The AI model reached an AUROC of 0.966 (95% CI, 0.960–0.972) and an AUPRC of 0.857 (95% CI, 0.836–0.877) on the in-distribution test set, and an AUROC of 0.899 (95% CI, 0.860–0.934) and an AUPRC of 0.498 (95% CI, 0.360–0.639) on the out-of-distribution test set. In the simulation experiment, using random case assignment as baseline, AI-based triaging prevented an average of 43.9 (95% CI, 36–55) initial examinations of high complexity cases by general pathologists for every 500 cases. In conclusion, the AI model achieved a strong predictive performance in differentiating between cutaneous melanocytic lesions of high and low complexity. The improvement in workflow efficiency due to AI-based triaging could be substantial.

Cutaneous melanoma is the fifth most common cancer in both the United States and the Netherlands^{1,2}. Over the last decades, the incidence rate of melanoma has consistently increased. In 2023, more than 97,000 people in the United States and more than 8000 people in the Netherlands were diagnosed with this type of skin cancer. Because of the relatively high risk of metastasis in melanoma patients, after which the prognosis significantly worsens, it is crucial to combine early detection, correct diagnosis, and fast treatment³.

Melanocytic skin lesions are clusters of pigment-producing cells called melanocytes, which range in terms of biological behavior from benign (nevus, also known as mole), intermediate (melanocytoma), to malignant (melanoma)⁴. Most of these lesions are benign and can be confidently diagnosed based only on microscopic examination of hematoxylin and

eosin (H&E)-stained tissue cross-sections. However, differentiating between some subtypes of melanocytic tumors is more challenging, with studies reporting low inter- and intra-observer agreement^{5,6}. Particularly for these ambiguous cases, immunohistochemical (IHC) staining and molecular testing can be helpful in making the correct diagnosis, at the cost of prolonging the turnaround time by days to weeks^{7,8}. While all melanocytic lesions should ideally be examined by specialized dermatopathologists, in many centers also general pathologists have to contribute to the examination of these lesions. To make matters worse, due to a growing volume of cases and the need for more comprehensive diagnoses, the workload for pathologists is expected to further increase⁹.

The transition to fully digital pathology departments enables the implementation of artificial intelligence (AI) models for workflow



[...] AUROC of 0.966 [...]

AI-based triaging prevented an average of 43.9 (95% CI, 36–55) initial examinations of high complexity cases by general pathologists for every 500 cases.

¹Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands. ²Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands. ³These authors contributed equally: Mitko Veta, Willeke A. M. Blokx. ✉e-mail: r.lucassen@umcutrecht.nl

Comparison to experts

Melanocytes

Eczema vs. palmoplantar Psoriasis

Journal of Cutaneous Pathology



ORIGINAL ARTICLE

Harnessing Digital Pathology Tools to Distinguish Hand Eczema From Palmor Psoriasis: A Quantitative Approach

Michael Ruckl¹, Peter Schuler¹, Julia Wenzel¹, Fabian Krennhuber¹, Michael Esterbauer¹, Michael Schuster¹, Corinna Becking¹, Markus V. Hager¹, Eliza A. T. Koch²

¹Department of Dermatology, University of Salzburg, Salzburg, Austria; ²Department of Dermatology, University of Vienna, Vienna, Austria; ³Department of Dermatology, University of Vienna, Vienna, Austria; ⁴Department of Dermatology, University of Vienna, Vienna, Austria; ⁵Department of Dermatology, University of Vienna, Vienna, Austria

Received 1 July 2023 / Accepted 15 October 2023 / Accepted 15 October 2023

Keywords: digital pathology; hand eczema; palmor psoriasis; histopathological features; machine learning

ABSTRACT

Background: Distinguishing hand eczema from palmor psoriasis is a common diagnostic challenge due to overlapping clinical and histopathological features.

Objective: This study aimed to utilize morphological and immunohistochemical criteria for differentiating these two conditions using deep learning tools.

Methods: Two hundred forty-two histopathological samples with confirmed digital pathology were stained with hematoxylin and eosin for routine analysis. Digital pathology tools were used to analyze the samples, and machine learning models were trained to distinguish between the two conditions.

Results: Histopathological features were significantly more pronounced in palmor psoriasis compared to hand eczema. Machine learning models achieved high accuracy in distinguishing between the two conditions.

Conclusion: Quantitative analysis of histopathological features and machine learning models can be used to distinguish between hand eczema and palmor psoriasis.

1 Introduction

Hand eczema and palmor psoriasis are common skin conditions that often overlap, making them difficult to distinguish. Both conditions are characterized by red, itchy, and scaly patches on the hands.

Hand eczema is a general inflammatory reaction of the skin, often triggered by irritants or allergens. It can be acute or chronic, and it often recurs. Palmor psoriasis is a chronic autoimmune condition that affects the palms of the hands.

Both conditions can be treated with topical corticosteroids, but the response is often limited. Therefore, it is important to have a reliable method for distinguishing between the two conditions.

Machine learning models have been used to analyze histopathological data and distinguish between different skin conditions. This study aimed to use machine learning to distinguish between hand eczema and palmor psoriasis.

This study was approved by the ethics committee of the University of Salzburg. The data were analyzed using machine learning models. The results of the study are presented in this article.

© 2023 John Wiley & Sons Ltd. Published by John Wiley & Sons Ltd.

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

Eczema vs. Psoriasis

ORIGINAL ARTICLE

Vision transformer-based diagnosis of psoriasis and eczema in whole-slide histology

Luca Carlos Rivera Murray^{1,2}, Anne Petzelt¹, Melissa Seif¹, Katharina Brunsing^{1,4}, Andreas Maier^{1,5}, Julia Vera-Gonzalez¹, Michael Esterbauer¹, Stefan Schlegel¹, Konstantin Drexler¹, Dennis Niesel¹, Stephan Schwenk¹, Klaus M. Hoyer¹, Yvonne Aulic¹, Stephan A. Ruzs¹, Paul Schenke¹, David Metz¹, Michael Schuster¹, Carola Berking¹, Eliza A.T. Koch², Markus V. Hager^{1,6}

Received 4 November 2023 / Revised 15 January 2024 / Accepted 15 February 2024

© 2024 The Authors. Journal of Cutaneous Pathology

ABSTRACT

Psoriasis and eczema are chronic inflammatory skin diseases with overlapping histopathological features, which often lead to diagnostic uncertainty even among experienced dermatologists. To address this challenge, we developed a computer-aided diagnostic framework that combines the ViT-based foundation model, pretrained on 1.2 million whole-slide images, with multi-instance learning (MIL) to classify psoriasis and eczema from digitized histopathology slides.

Using an internal dataset (n = 40) and an external validation cohort (n = 40), equally balanced between both conditions and annotated by board-certified dermatopathologists, our best-performing configuration (ViTbase + CLAM) achieved 87% accuracy, 87% sensitivity, 87% specificity, and an F1 score of 0.87, and an AUC of 0.81 on the external cohort. This substantially improved baseline conditions established by dermatologists, which reached 75% accuracy, and models relying solely on pre-trained feature extractors achieved 68% accuracy.

Our results suggest that the ViT-based foundation model, pretrained on 1.2 million whole-slide images, can be used to distinguish between psoriasis and eczema from digitized histopathology slides. This approach is scalable and can be adapted to other skin conditions.

Conclusion: Quantitative analysis of histopathological features and machine learning models can be used to distinguish between psoriasis and eczema from digitized histopathology slides.

Keywords: digital pathology; psoriasis; eczema; machine learning; histopathological features; vision transformer

Introduction

Psoriasis and eczema are chronic inflammatory skin diseases that significantly impact quality of life. Psoriasis affects 2–3% of the global population and presents as erythematous plaques with silvery scaling, commonly found on the scalp, elbows, and knees. It is primarily driven by T-cell dysregulation and proinflammatory cytokines such as TNF- α , IL-17, and IL-23/17. Eczema, by contrast, affects up to 20% of children and 10% of adults [1], presenting as pruritic, inflamed patches, particularly in flexural areas, and is associated with Th2-mediated responses involving IL-4, IL-13, and IL-31.

Both conditions are characterized by chronic inflammation, which often leads to diagnostic uncertainty even among experienced dermatologists.

Recent years have seen the emergence of machine learning models for skin disease diagnosis. These models have shown promising results in distinguishing between different skin conditions.

This study aimed to use machine learning to distinguish between psoriasis and eczema from digitized histopathology slides. The results of the study are presented in this article.

This study was approved by the ethics committee of the University of Salzburg. The data were analyzed using machine learning models. The results of the study are presented in this article.

© 2024 The Authors. Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 John Wiley & Sons Ltd. Published by John Wiley & Sons Ltd.

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

© 2024 The Authors

Journal of Cutaneous Pathology

DOI: 10.1111/jcp.15555

Drug eruption vs. Atopic dermatitis vs. Normal

Journal of Imaging Medicine in Medicine

https://doi.org/10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine

DOI: 10.1002/jim.1519

© 2024 The Authors

Journal of Imaging Medicine in Medicine



ARTICLE

Artificial neural networks and pathologists recognize basal cell carcinomas based on different histological patterns

Susanne Kimeswenger^{1,2,3} · Philipp Tschandl⁴ · Petar Noack⁵ · Markus Hofmarcher⁶ · Elisabeth Rumetshofer⁶ · Harald Kindermann⁷ · Rene Silye² · Sepp Hochreiter⁶ · Martin Kaltenbrunner^{2,3} · Emmanuella Guenova^{8,9} · Guenter Klambauer⁶ · Wolfram Hoetzenecker¹

Received: 1 August 2020 / Revised: 14 October 2020 / Accepted: 15 October 2020 / Published online: 13 November 2020
© The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2020

Abstract

Recent advances in artificial intelligence, particularly in the field of deep learning, have enabled researchers to create compelling algorithms for medical image analysis. Histological slides of basal cell carcinomas (BCCs), the most frequent skin tumor, are accessed by pathologists on a daily basis and are therefore well suited for automated prescreening by neural networks for the identification of cancerous regions and swift tumor classification.

In this proof-of-concept study, we implemented an accurate and intuitively interpretable artificial neural network (ANN) for the detection of BCCs in histological whole-slide images (WSIs). Furthermore, we identified and compared differences in the diagnostic histological features and recognition patterns relevant for machine learning algorithms vs. expert pathologists.

An attention-ANN was trained with WSIs of BCCs to identify tumor regions ($n = 820$). The diagnosis-relevant regions used by the ANN were compared to regions of interest for pathologists, detected by eye-tracking techniques.

This ANN accurately identified BCC tumor regions on images of histologic slides (area under the ROC curve: 0.993, 95% CI: 0.990–0.995; sensitivity: 0.965, 95% CI: 0.951–0.979; specificity: 0.910, 95% CI: 0.859–0.960). The ANN implicitly calculated a weight matrix, indicating the regions of a histological image that are important for the prediction of the network. Interestingly, compared to pathologists' eye-tracking results, machine learning algorithms rely on significantly different recognition patterns for tumor identification ($p < 10^{-4}$).

To conclude, we found on the example of BCC WSIs, that histopathological images can be efficiently and interpretably analyzed by state-of-the-art machine learning techniques. Neural networks and machine learning algorithms can potentially enhance diagnostic precision in digital pathology and uncover hitherto unused classification patterns.

These authors contributed equally: Emmanuella Guenova, Guenter Klambauer, Wolfram Hoetzenecker

Supplementary information The online version of this article (<https://doi.org/10.1038/s41379-020-00712-7>) contains supplementary material, which is available to authorized users.

✉ Wolfram Hoetzenecker
wolfram.hoetzenecker@kepleruniklinikum.at

¹ Johannes Kepler University Linz, Kepler University Hospital Linz, Department of Dermatology, Linz, Austria

² Johannes Kepler University Linz, Institute of Applied Physics, Department of Soft Matter Physics, Linz, Austria

³ Johannes Kepler University Linz, Linz Institute of Technology, Soft Materials Lab, Linz, Austria

⁴ Medical University of Vienna, Department of Dermatology, Vienna, Austria

Introduction

Digital pathology, i.e., the management and clinical interpretation of information retrieved from digitalized histology slides, aims to improve the safety, quality, and accuracy of

⁵ Kepler University Hospital Linz, Department of Pathology and Microbiology, Linz, Austria

⁶ Johannes Kepler University Linz, Institute for Machine Learning, Linz, Austria


⁷ University of Applied Sciences, Upper Austria, Marketing and Electronic Business, Steyr, Austria

⁸ University of Lausanne, Faculty of Biology and Medicine, Department of Dermatology, Lausanne, Switzerland


⁹ University Hospital of Zurich, Department of Dermatology, Zurich, Switzerland

SPRINGER NATURE

Kimeswenger 2021: “[...] achieved 99.3% accuracy in identifying basal cell carcinoma tumor regions on histological slides, [...]”




Dataset: “Sections of BCCs and normal skin”



TRAINING

“Apple”



“Strawberry”




TEST




?

Special, rare and problematic subtypes often not included



The most relevant thing to create and evaluate a classifier **is the dataset**



Hallucinations

Careless Whisper: Speech-to-Text Hallucination Harms

ALLISON KOENECKE, Cornell University, USA

ANNA SEO GYEONG CHOI*, Cornell University, USA

KATELYN X. MEI*, University of Washington, USA

HILKE SCHELLMANN†, New York University, USA

MONA SLOANE†, University of Virginia, USA

[~] **1%** of audio transcriptions contained entire **hallucinated phrases or sentences** which did not exist in any form in the underlying audio.

38% of hallucinations **include explicit harms** such as perpetuating violence, making up inaccurate associations, or implying false authority

	<i>Dependent variable:</i>
	Hallucination
Share of Duration Being Non-Vocal	0.951** (0.438)
Number of Words	0.056*** (0.011)
Has Aphasia	0.368* (0.204)
Is Female	-0.017 (0.168)
Age	0.044 (0.043)
Age Squared	-0.0004 (0.0004)
African American	-0.132 (0.469)
Other Race	-0.281 (0.518)
Years of Education	-0.058* (0.033)
English is First Language	-0.227 (1.035)
No Vision Loss	0.395 (1.026)
No Hearing Loss	0.500 (1.028)
Constant	-6.447*** (2.175)
Observations	10,830
Log Likelihood	-783.942
Akaike Inf. Crit.	1,593.883

Note:



*p<0.1; **p<0.05; ***p<0.01


Learning with language models

33y, female
Axillary changes since
4-5 years, increasing

"DD: Steatocystoma"



No photograph






The screenshot shows a web browser window. The address bar displays 'chat.mistral.ai/inco' with a lock icon and a '80%' zoom level. The page content is a chat interface with a light gray background. A text input area at the top contains the following text: 'Female Patient, 33 years', 'Clinic: Multiple axillary skin colored papules since 4 years', 'Dermatopathology: Perifollicular fibrosis with foam cells, prominent apocrine glands', and 'Diagnosis or differential diagnoses?'. The text is entered in a white input box with a light gray border. The browser's address bar also shows 'Exit Incognito mode' and a clock icon indicating the time is 9:06.

Female Patient, 33 years
Clinic: Multiple axillary skin colored papules since 4 years
Dermatopathology: Perifollicular fibrosis with foam cells, prominent apocrine glands
Diagnosis or differential diagnoses?



Fox-Fordyce disease (“Apocrine miliaria”)



[...] impossible to decide, whether Fox-Fordyce disease is an inflammatory condition or a genetically determined alteration of cornification [...]. The [...] pathogenesis [...] remains to be elucidated, [...] signs [...] evolve only during fertility, preponderantly of women, when the function of apocrine glands is increasing; after the menopause, the lesions subside.

Böer A. Patterns
histopathologic of
Fox-Fordyce disease.
Am J Dermatopathol.
2004 Dec;26(6):482-
92.

Sycophancy

“Chatbots ass-kissing”

Science

AAAS

TOXIC PRAISE

Harms of AI chatbots' sycophancy, flattery, and overly agreeable advice
pp. 1316 & 1348

Sycophancy in AI responses is pervasive and alters people's behavioral inclinations. (Left) On personal advice queries, AI models affirm users' actions 49% more often than crowdsourced human responses. (Right) In experiments where participants discussed real interpersonal conflicts, sycophantic AI increased participants' conviction that they were right and their desire to keep using the model, while reducing their willingness to repair the conflict.


26 MAY 2024

The plants that drought can't kill p. 1312
Satellite sees a tsunami's finer physics p. 1368
Demonstrating parallel evolution at a global scale p. 1346

Prevalence of sycophancy in AI



Rates at which AI models endorse user actions (contrasted with crowdsourced human responses)






Effects of sycophantic AI

Participants discuss real personal conflicts with non-sycophantic AI OR sycophantic AI



Post-interaction measures



Sycophantic Chatbots Cause Delusional Spiraling, Even in Ideal Bayesians

Kartik Chandra¹, Max Kleiman-Weiner², Jonathan Ragan-Kelley¹ & Joshua B. Tenenbaum³


¹MIT CSAIL

²University of Washington, Seattle

³MIT Department of Brain & Cognitive Sciences

"AI psychosis" or "delusional spiraling" is an emerging phenomenon where AI chatbot users find themselves dangerously confident in outlandish beliefs after extended chatbot conversations.

[...] even an idealized [...] rational user is vulnerable to delusional spiraling, and that sycophancy plays a causal role.



RESEARCH

A new direction for students in an AI world: Prosper, prepare, protect

Mary Burns, Rebecca Winthrop, Natasha Luther, Emma Venetis, and Rida Karim
January 14, 2026



Children use tablets in the cla

<https://www.brookings.edu/articles/a-new-direction-for-students-in-an-ai-world-prosper-prepare-protect/> [2026-01-17]

Recommendations

1. Shift educational experiences in school.
2. Co-create educational AI tools with educators, students, parents, and communities.
3. Use AI tools that teach, not tell.
4. Conduct research on children's learning and development in an AI world.
5. Promote holistic AI literacy for students, teachers, parents, and education leaders.
6. Prepare teachers to teach with and through AI.
7. Provide a clear vision for ethical AI use that centers human agency.
8. Employ innovative financing strategies to close the AI divide.
9. Break the engagement addiction and design platforms that are centered around positive mental health for children and youth.
10. Establish comprehensive regulatory frameworks for educational AI.
11. Procure technology that protects students' privacy, safety, and security.
12. Support families to manage children's AI use at home.

LLMs for education should be forced
to behave antagonistically

Missing today

- Foundation Models
- Benchmarks
- Taxonomies
- Agents
- Workflows
- Vision-Language models
- Calibration
- Predicting prognosis
- Predicting mutations
- Predicting therapy response
- Detection & Counting
- Smart searching
- Biases and confounders
- Color assessment and normalization
- ...

Interest in collaboration!

- Consensus on **terminology**
- **Automated semantic coding** of dermatopathology texts
- Holistic and free dermatopathology **datasets**
- **Human-Computer Interaction** with digital platforms
- Assessment and creation of **DermPath Foundation Models**

Philipp TSCHANDL

Department of Dermatology

Medical University of Vienna

philipp.tschandl@meduniwien.ac.at

